FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APP	ROVAL
OMB Number:	3235-0104
Estimated average I	
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			or Sect	1011 30(11) 01	the mve	istinent Company Act of 1s	940				
	dress of Reporting	W (2. Date of Event Requiring Stater Month/Day/Yea L0/07/2015	ment		er Name and Ticker or TracemX Therapeutics,		MX]			
(Last) 743 SAN YSI	(First)	(Middle)				tionship of Reporting Perso all applicable) Director	on(s) to Issue			Amendment, Da th/Day/Year)	ate of Original Filed
(Street) SANTA BARBARA	CA	93108				Officer (give title below)	Other (spe- below)	cify		cable Line) Form filed by	/Group Filing (Check y One Reporting Person y More than One erson
(City)	(State)	(Zip)									
		7	Table I - Nor	n-Derivati	ive Se	curities Beneficiall	ly Owned				
1. Title of Secur	ity (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)		Beneficial Ownership							
Common Stoc	k					137,791	D				
Common Stock				3,200		I F		By spouse			
		(e. _:				urities Beneficially ptions, convertible		s)			
1. Title of Deriva	ative Security (In	Expiration Date (Month/Day/Year) Underlying Derivative Security (Instr. 4) Co		Conver or Exer	cise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)				
			Date Exercisable	Expiration Date	Title		Amount or Number of Shares	Price o Derivat Securit	ive	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option ((right to buy)		(1)	03/23/2021		Common Stock	31,767	1.13	39	D	
Stock Option ((right to buy)		(2)	02/25/2023		Common Stock	16,612	0.94	4 5	D	
Stock Option ((right to buy)		(3)	05/23/2024		Common Stock	27,606	1.44	89	D	
Stock Option	(right to buy)		(4)	02/08/2025		Common Stock	17,139	1.57	49	D	

Explanation of Responses:

- 1. This option vested 25% on September 22, 2011, and the remaining 75% vested in 36 substantially equal monthly installments thereafter.
- 2. This option vested in 24 substantially equal monthly installments starting on the last day of February 2013.
- $3. \ This \ option \ vests \ in \ 24 \ substantially \ equal \ monthly \ installments \ starting \ on \ the \ last \ day \ of \ April \ 2014.$
- 4. This option vests in 12 substantially equal monthly installments starting on the last day of January 2015.

Remarks:

Exhibit 24.1 - Power of Attorney

/s/ Cynthia J. Ladd, attorney-

** Signature of Reporting Person

in-fact

<u>10/07/2015</u>

Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Robert C. Goeltz II and Cynthia J. Ladd, or either of them acting individually, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of <u>CytomX Therapeutics</u>, <u>Inc</u>. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 14th day of September, 2015.

/s/ Frederick W. Gluck	
Signature	
3	
Frederick W. Gluck	
Flederick W. Gluck	
Print Name	